Usage And Safety
Dosage
Duodenal ulcer: 2 Tablets (1 g ) twice a day or 2 teaspoonful (1 g susp. twice a day. Gastric ulcer: 1 Tablet (1 g 3 to 4 times a day). Or 1 teaspoonful ( 1 g susp.) 3 to 4 times a day. Relapse prophylaxis of gastric and duodenal ulcer: 2 Tablets (1 g ) once a day or 2 teaspoonful (1 g susp.) once a day. Reflux esophagitis: 1 Tablet ( 1 g ) 4 times a day or 1 teaspoonful ( 1 g susp. ) 4 times a day. Stress ulcer prophylaxis: 1 tablet ( 1 g ) every 4 hours or 1 teaspoonful ( 1 g susp. ) every 4 hours. For short-term treatment of gastric and duodenal ulcer: 1 g is taken before meals and the 4th dose in the evening at bedtime. Alternatively 2 g may be taken in the morning on rising and 2g in the evening at bedtime. For short-term treatment of reflux esophagitis: 1 g is taken after meals and at bedtime. OR As directed by your physician.
Side Effects
Nervous system disorders : Less frequent: Dizziness, drowsiness , Frequency unknown: Vertigo ; Skin and subcutaneous tissue disorders : Less frequent: Skin rashes, pruritus ; Gastrointestinal disordersFrequent: Constipation Less frequent: Diarrhoea, nausea, dry mouth, gastric discomfort.
Drug Interactions
Cimetidine, ranitidine, digoxin, ketoconazole, phenytoin, fluoroquinolone antibacterials, tetracycline, levothyroxine, quinidine, theophylline and possibly warfarin.
Indication
It is used to treat : Gastric ulcer, duodenal ulcer, chronic gastritis and reflux oesophagitis. • It produces relief of subjective symptoms of peptic ulceration e.g. epigastric pain, hyperchlorhydria, vomiting. •Maintenance treatment after successful endoscopically proven, recently healed duodenal ulcer.
When not to Use
Hypersensitivity to sucralfate or to any of the excipients found in this product.
Warnings
Warning 1
Aluminium accumulation and toxicity (aluminium osteodystrophy, osteomalacia, encephalopathy) have been described in patients with renal impairment. Blood levels of aluminium, phosphate, calcium, alkalinephosphatase, should be periodically measured in these patients.
Warning 2
Caution is advised when sacralfate is administered in patients with phosphate deficiencies as aluminium binds to phosphate in the gastrointestinal tract, inhibiting its absorption.
Warning 3
Occasional cases of bezoar (an insoluble mass formed within the gastric lumen) have been reported in patients taking sucralfate. Bezoars have been described in patients after administration of sucralfate in severely ill patients in Intensive Care Units, and especially in premature infants in whom the use of sucralfate is not recommended, and should be used with caution in patients with delayed gastric emptying or receiving concomitant enteral feeds.
